Clinical trial · no report yet · Phase 2
NCT03330847
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
- NCT03330847 ↗
- Active, not recruiting
- AstraZeneca
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Triple Negative Breast Cancer
- Interventions
- Olaparib Continuous (28-Day cycle) 300 mg BD.; Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).; Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
- Arms
- Olaparib monotherapy · Active comparator
- Olaparib+Ceralasertib · Active comparator
- Olaparib+adavosertib · Active comparator
- Enrollment
- 273
- Primary outcomes
- Progression-free Survival Per Stratum (BICR)
- Progression-free Survival Per Stratum (Sensitivity Analysis)
- Sponsor
- AstraZeneca
- Start
- Mar 7, 2018
- Primary completion
- Nov 13, 2020
- Results posted
- Yes
- Registry record
- NCT03330847 · updated Oct 14, 2026
Publications
linked from the registry- Smith G, Alholm Z, Coleman RL, Monk BJ. DNA Damage Repair Inhibitors-Combination Therapies. Cancer J. 2021 Nov-Dec 01;27(6):501-505. doi: 10.1097/PPO.0000000000000561. PubMed 34904813